GPX4 and breast carcinoma: BRCA1 deficiency induces ferroptosis vulnerability to PARP and GPX4 co-inhibition, which is useful for therapeutic strategies to overcome PARP inhibitor resistance in BRCA1-deficient cancers, including breast cancer [32].